| 18-803 |
Wendy B. Dolin v. GlaxoSmithKline, LLC, fka SmithKline Beecham Corporation |
Seventh Circuit |
2018-12-21 |
Denied |
Relisted (2) |
clinical-trials drug-labeling drug-manufacturer fda-regulations impossibility-preemption labeling-changes preemption truthful-risks unilateral-labeling-changes unilateral-warning wyeth-v-levine |
Does federal law prevent a drug manufacturer from enhancing its label to reflect truthful risks revealed in its clinical trials when the relevant FDA … |